These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 35947166)

  • 1. Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.
    Coutens B; Yrondi A; Rampon C; Guiard BP
    Psychopharmacology (Berl); 2022 Sep; 239(9):2735-2752. PubMed ID: 35947166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.
    Aldosary F; Norris S; Tremblay P; James JS; Ritchie JC; Blier P
    Int J Neuropsychopharmacol; 2022 Apr; 25(4):283-292. PubMed ID: 34958348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential physiological effects of a low dose and high doses of venlafaxine in major depression.
    Debonnel G; Saint-André E; Hébert C; de Montigny C; Lavoie N; Blier P
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):51-61. PubMed ID: 16690006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
    Stahl SM; Grady MM; Moret C; Briley M
    CNS Spectr; 2005 Sep; 10(9):732-47. PubMed ID: 16142213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder.
    Fagiolini A; Cardoner N; Pirildar S; Ittsakul P; Ng B; Duailibi K; El Hindy N
    Expert Opin Pharmacother; 2023; 24(15):1715-1723. PubMed ID: 37501324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
    Beyer CE; Boikess S; Luo B; Dawson LA
    J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine versus other antidepressive agents for major depression.
    Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psychopharmacological profile of venlafaxine].
    Bourin M
    Encephale; 1999 Jun; 25 Spec No 2():21-2; discussion 23-5. PubMed ID: 10434156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venlafaxine: a novel antidepressant that has a dual mechanism of action.
    Andrews JM; Ninan PT; Nemeroff CB
    Depression; 1996; 4(2):48-56. PubMed ID: 9160640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
    Ishigooka J
    Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.
    Béïque J; de Montigny C; Blier P; Debonnel G
    Neuropharmacology; 2000 Jul; 39(10):1800-12. PubMed ID: 10884561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of venlafaxine in the treatment of severe depression.
    Kienke AS; Rosenbaum JF
    Depress Anxiety; 2000; 12 Suppl 1():50-4. PubMed ID: 11098414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat.
    Béïque J; de Montigny C; Blier P; Debonnel G
    Neuropharmacology; 2000 Jul; 39(10):1813-22. PubMed ID: 10884562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
    Millan MJ; Dekeyne A; Papp M; La Rochelle CD; MacSweeny C; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2001 Aug; 298(2):581-91. PubMed ID: 11454919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.